Please try another search
Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company’s lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Peter Buhl Jensen | 68 | 2021 | Independent Chairman of the Board |
Marcus Larsson | 50 | 2015 | Founding Member, CEO & Director |
Christopher Bravery | 56 | 2021 | Independent Director |
Fredrik Tiberg | 60 | 2021 | Independent Director |
Ingrid Atteryd Heiman | 65 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review